Selective Cyclooxygenase‐2 Inhibition Prevents Alveolar Bone Loss in Experimental Periodontitis in Rats
- 1 June 2000
- journal article
- research article
- Published by Wiley in The Journal of Periodontology
- Vol. 71 (6), 1009-1014
- https://doi.org/10.1902/jop.2000.71.6.1009
Abstract
Prostaglandins are implicated in periodontal bone destruction. We investigated the effect of a non-selective cyclooxygenase (COX) inhibitor (indomethacin-IND) or a type 2 COX inhibitor (meloxicam-MLX) in an experimental periodontal disease (EPD) model. Wistar rats were subjected to placement of a nylon thread ligature around the maxillary molars and sacrificed after 7 days. Alveolar bone loss (ABL) was measured in one quadrant as the distance between the cemento-enamel junction and the alveolar bone. The other quadrant was processed for histopathologic analysis. Daily weight and white blood cell count were recorded. Groups were treated subcutaneously for 7 days with either IND (0.5, 1, or 2 mg/kg) or MLX (0.75, 1.5, or 3 mg/kg). Controls received no treatment. Macroscopic analysis of the gastric mucosa was done. The control group did not receive any manipulation, and a non-treated group consisted of rats subjected to periodontitis that received no pharmacological treatment. In the non-treated (NT) group, there was significant ABL, severe mononuclear influx, and an increase in osteoclast numbers. Significant neutrophilia and lymphomonocytosis occurred at 6 hours and at 7 days, respectively, as compared to controls. Significant weight loss persisted until the seventh day in the NT group. Both IND and MLX reduced ABL and histopathologic changes. Neutrophilia and lymphomonocytosis were also significantly reversed. Both IND and MLX induced earlier weight recovery. The stomachs of the IND (1 and 2 mg/kg) groups presented hemorrhage and ulcers, whereas in the MLX-treated groups, there were mild petechiae just in the 3 mg/kg group. COX inhibition prevented ABL in this experimental periodontal disease model. MLX displays similar efficacy and less gastric damage than IND. MLX may provide a better risk/benefit ratio in the treatment of human periodontitis than non-selective COX inhibitors.This publication has 17 references indexed in Scilit:
- Cyclooxygenase 1 and 2 in rheumatic disease: Implications fornonsteroidal anti-inflammatory drug therapySeminars in Arthritis and Rheumatism, 1996
- Pharmacology of Meloxicam, A New Non-Steroidal Anti-Inflammatory Drug with an Improved Safety Profile Through Preferential Inhibition of COX-2Rheumatology, 1996
- Mechanism of Action of Anti-Inflammatory DrugsScandinavian Journal of Rheumatology, 1996
- Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal toleranceInflammation Research, 1995
- Towards a better aspirinNature, 1994
- Modulation of Host PGE2 Secretion as a Determinant of Periodontal Disease ExpressionThe Journal of Periodontology, 1993
- A quantitative method for assessing the extent of experimental gastric erosions and ulcersJournal of Pharmacological Methods, 1985
- Alveolar bone destruction in the immunosuppressed ratJournal of Periodontal Research, 1982
- The natural history of periodontal bone loss in germfree and gnotobiotic rats infected with Periodontopathic microorganismsJournal of Periodontal Research, 1978
- Conversion of stable established gingivitis in the dog into destructive periodontitisArchives of Oral Biology, 1975